Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VP4896 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| VP4896 | DRUG | - |
Inclusion Criteria: * 60 years of age or older * Diagnosis of probable mild-to-moderate Alzheimer's Disease * On a stable dose of an acetylcholinesterase inhibitor (including, but not limited to: donepezil, galantamine, rivastigmine, and tacrine) for at least 120 days prior to baseline and will lik...
Top 20 of 25 competitors
VP4896 is an investigational small molecule being studied for the treatment of Alzheimer's Disease. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities. The drug is being evaluated in patients aged 60 years and older.
VP4896 is being developed by Voyager Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VYGR. The company is conducting clinical trials to evaluate the drug's safety and efficacy in Alzheimer's Disease.
VP4896 is in Phase 3 clinical development for Alzheimer's Disease. It is an investigational drug, meaning it has not yet received regulatory approval and is still undergoing clinical trials to assess its safety and effectiveness in the target patient population.
VP4896 has one completed Phase 3 clinical trial registered under NCT00231946, titled the ALADDIN Study. This randomized, double-blind trial enrolled 555 participants with Alzheimer's Disease across the United States and Canada, with a minimum age of 60 years.
VP4896 is associated with the clinical trial VP-AD-301, which is the study identifier for the ALADDIN Phase 3 trial. The drug is being investigated under this trial protocol for the treatment of Alzheimer's Disease, though the drug itself is referred to as VP4896.